Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1628456 | 1.00 | MAPT (0.54) | MAPTSMN1; SMN2LIN28ATDP1TERT | |
| SCHEMBL12722530 | 0.94 | TDP1 (0.65) | MAPTSMN1; SMN2LIN28ATDP1TERT | |
| SCHEMBL13924708 | 0.94 | TDP1 (0.65) | MAPTSMN1; SMN2LIN28ATDP1TERT | |
| SCHEMBL12087481 | 0.88 | TDP1 (0.56) | MAPTSMN1; SMN2LIN28ATDP1TERT | |
| SCHEMBL18997980 | 0.86 | CYP2D6 (0.52) | MAPTSMN1; SMN2LIN28ATDP1TERT | |
| SCHEMBL369262 | 0.83 | TSHR (0.45) | SMN1; SMN2KMT2AMEN1LMNATSHR | |
| SCHEMBL138261 | 0.79 | SMN1; SMN2 (0.83) | MAPTSMN1; SMN2LIN28ATDP1TERT | |
| SCHEMBL12087478 | 0.78 | CYP3A4 (0.39) | SMN1; SMN2KMT2AMEN1LMNATSHR | |
| SCHEMBL14357958 | 0.77 | MAPT (0.79) | MAPTSMN1; SMN2LIN28ATDP1TERT | |
| Hydrochloric Acid SCHEMBL9905725 | 0.77 | SMN1; SMN2 (0.79) | MAPTSMN1; SMN2LIN28ATDP1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179249-A1 | METHODS AND KITS FOR REMOVING CALCULUS USING A NON-ENZYMATIC, HYDROGEN PEROXIDE DECOMPOSITION CATALYST | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2020-06-11 | — | — | US | disclosed |
| US-8951695-B2 | Redox fuel cell with catholyte redox mediator | ACAL ENERGY LIMITED (GB) | 2015-02-10 | — | — | US | disclosed |
| US-8951695-B2 | Redox fuel cell with catholyte redox mediator | ACAL ENERGY LIMITED (GB) | 2015-02-10 | — | — | US | disclosed |
| US-8951695-B2 | Redox fuel cell with catholyte redox mediator | ACAL ENERGY LIMITED (GB) | 2015-02-10 | — | — | US | disclosed |
| EP-2238641-B1 | REDOX FUEL CELLS | ACAL ENERGY LTD (GB) | 2012-09-05 | — | — | EP | disclosed |
| EP-2238641-B1 | REDOX FUEL CELLS | ACAL ENERGY LTD (GB) | 2012-09-05 | — | — | EP | disclosed |
| US-20110091746-A1 | FUEL CELLS | ACAL ENERGY LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| US-20110091746-A1 | FUEL CELLS | ACAL ENERGY LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| US-20110091746-A1 | FUEL CELLS | ACAL ENERGY LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| EP-2238641-A1 | FUEL CELLS | Acal Energy Limited (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009093080-A1 | FUEL CELLS | ACAL ENERGY LIMITED (GB) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093080-A1 | FUEL CELLS | ACAL ENERGY LIMITED (GB) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009013313-A1 | TOC DEGRADATION IN WASTEWATER USING TRANSITION METAL CATALYSTS | HENKEL AG & CO. KGAA (DE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179249-A1 | METHODS AND KITS FOR REMOVING CALCULUS USING A NON-ENZYMATIC, HYDROGEN PEROXIDE DECOMPOSITION CATALYST | HAO2, LPO, HAO1 | MAPT 4850/4885SMN1; SMN2 4863/4885LIN28A 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.